Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:41 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1315
Shown on this page
12
Current sort
Recently updated
Campus scope
Cleveland Clinic, Cleveland, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cleveland Clinic, Cleveland, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 901–912 of 1,315 matching trials with a site at Cleveland Clinic, Cleveland, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

NCT05020912
Site status not listed — check the official record
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
ALA, PDT
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Active, not recruiting Phase 1 Interventional

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Interventions
Anvumetostat, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX, RMC-6236
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Bakersfield, California • Duarte, California • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT04938817
Site status not listed — check the official record
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830, coformulation favezelimab/pembrolizumab, R-DXd
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

NCT03330821
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia
Interventions
Cytarabine, Idarubicin, Laboratory Biomarker Analysis, Pevonedistat, Pharmacological Study
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Active, not recruiting Phase 3 Interventional Results available

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01167712
Site status not listed — check the official record
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Bevacizumab, Carboplatin, Computed Tomography, Paclitaxel, Therapeutic Conventional Surgery
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
559
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 374 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Active, not recruiting Phase 3 Interventional Results available

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856
Site status not listed — check the official record
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Enfortumab vedotin, Pembrolizumab, Cisplatin, Carboplatin, Gemcitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Tucson, Arizona • Burbank, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Recruiting Phase 2 Interventional

Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

NCT06657924
Status at this site: Recruiting
View directory record Official record
Conditions
Bleeding, Colorectal Disorders, Thromboembolism, Tranexamic Acid
Interventions
Tranexamic acid
Drug
Lead sponsor
Kristen Ban
Other
Eligibility
18 Years to 100 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Not yet recruiting Not applicable Interventional

Shape-sensing Versus Electromagnetic Robotic Bronchoscopy for Evaluation of PulmoNary LEsions

NCT07411989
Site status not listed — check the official record
View directory record Official record
Conditions
Peripheral Pulmonary Lesions (PPLs), Lung Nodules
Interventions
Bronchoscopy for peripheral pulmonary lesion biopsy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Active, not recruiting Phase 3 Interventional

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
86
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Active, not recruiting Not applicable Interventional

Assessment of Combined CCM and ICD Device in HFrEF

NCT05855135
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Interventions
OPTIMIZER® Integra CCM-D System (Treatment Arm)
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Recruiting Not applicable Interventional

Gastroschisis Outcomes of Delivery (GOOD) Study

NCT02774746
Status at this site: Recruiting
View directory record Official record
Conditions
Gastroschisis
Interventions
35-week delivery, 38-week delivery
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
38
States / cities
Phoenix, Arizona • Loma Linda, California • Stanford, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 2, 2026, 3:41 PM EST
Active, not recruiting No phase listed Observational

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

NCT03615235
Site status not listed — check the official record
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • San Francisco, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 2, 2026, 3:41 PM EST

About this Cleveland Clinic institution page

What this page lists
ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.